BioCentury
ARTICLE | Clinical News

PRO 140: Phase III started

June 15, 2015 7:00 AM UTC

CytoDyn began a double-blind, placebo-controlled, U.S. Phase III trial to evaluate self-injectable PRO 140 as part of a highly active anti-retroviral therapy (HAART) regimen for 25 weeks in 300 treatm...